RPE Tear: When Treating the PED Successfully Backfires

Retinal pigment epithelial (RPE) tear is a recognized complication of neovascular age-related macular degeneration, occurring most often in eyes with a large pigment epithelial detachment (PED) that is being treated with anti-VEGF therapy, and it represents a genuine and somewhat frustrating clinical paradox — the very treatment that successfully controls choroidal neovascularization and reduces fluid can, in certain higher-risk eyes, precipitate a sudden, often vision-limiting tear of the RPE layer itself.

Mechanism

A large fibrovascular or serous PED creates significant tangential (shearing) stress across the RPE monolayer as it is stretched over an elevated dome of subretinal fluid or fibrovascular tissue.

Anti-VEGF treatment rapidly reduces fluid and induces contraction of the underlying choroidal neovascular membrane, and this sudden contraction can generate enough additional shearing force across an already stretched, structurally vulnerable RPE layer to cause it to tear — typically at the junction between the still-attached and detached RPE, where the mechanical stress is concentrated.

The RPE layer then retracts, exposing bare choroid in the area of the tear while the retracted RPE tissue rolls up elsewhere, usually still attached at one edge.

Risk Factors

• Large PED height and diameter — the single most consistently identified risk factor, with larger, more elevated PEDs carrying substantially higher tear risk than smaller ones
• A predominantly serous (rather than purely fibrovascular) PED composition
• The specific type and characteristics of the underlying choroidal neovascular membrane
• Rapid, robust treatment response to anti-VEGF therapy — somewhat counterintuitively, eyes that respond most dramatically to treatment, with rapid PED collapse, appear to carry a higher tear risk than those with a more gradual response

Given this risk profile, patients with a large PED being started on anti-VEGF therapy should be counseled about the possibility of RPE tear as a recognized complication before treatment begins, so that any sudden change in vision after an injection is reported and evaluated promptly rather than assumed to simply reflect expected treatment variability.

Clinical Presentation

Patients typically notice sudden, sometimes significant, painless vision loss, often within days of an anti-VEGF injection, corresponding to the timing of PED contraction described above.

Because the underlying disease (neovascular AMD) already causes some baseline visual impairment, a new, more abrupt change should be specifically recognized as potentially representing a tear rather than simply attributed to disease progression or normal fluctuation.

Exam and Imaging Findings

• A sharply demarcated area of exposed, depigmented choroid where the RPE has torn away, often with a visible, rolled or scrolled edge of retracted RPE tissue at the margin, sometimes appearing as a crescentic or horseshoe-shaped darker band adjacent to the pale, exposed area
• OCT clearly demonstrates the RPE discontinuity, showing the retracted, folded RPE layer and the adjacent area where the RPE-Bruch’s membrane complex is now absent, with the underlying choroid directly visible
• The area of RPE tear, since the RPE normally forms part of the outer blood-retina barrier and also nourishes the overlying photoreceptors, generally corresponds to permanently reduced function if the tear involves the fovea, regardless of how well the underlying neovascular activity is subsequently controlled

Differential Diagnosis

• Progression of the underlying choroidal neovascularization or geographic atrophy — a more gradual process than the typically sudden onset of a true RPE tear, and without the specific rolled-edge, exposed-choroid appearance characteristic of a tear on exam and OCT
• Submacular hemorrhage — a different, though sometimes coexisting, complication of neovascular AMD, distinguished by the presence of blood rather than a clean area of RPE discontinuity
• Central serous chorioretinopathy-related PED changes — a different underlying disease process with its own characteristic findings, discussed in this site’s coverage of that condition

Management

There is no treatment that repairs or reverses an established RPE tear itself; management focuses on continuing appropriate anti-VEGF therapy for any persistent or recurrent choroidal neovascular activity in the areas surrounding the tear, since the underlying neovascular disease still requires ongoing control even though the tear itself cannot be undone.

Some clinicians consider adjusting anti-VEGF treatment strategy (such as considering a somewhat more gradual treatment approach or closer monitoring) in high-risk eyes with a large PED, given the recognized association between rapid treatment response and tear risk, though this needs to be balanced against the clear overall benefit of anti-VEGF treatment for controlling the neovascular disease itself.

Prognosis

Visual outcome after RPE tear depends heavily on whether the fovea is involved in the torn (rather than the retracted, still-present) area — tears sparing central foveal RPE can be associated with relatively preserved central vision, while foveal involvement generally results in permanent, significant central visual impairment given the RPE’s essential supportive role for the overlying photoreceptors.

Because of this direct relationship between tear location and visual outcome, and because tears can occur even with appropriate, guideline-concordant anti-VEGF treatment, patient counseling about this risk — rather than any specific preventive strategy with strong proven efficacy — remains the primary practical tool available before treatment begins in a high-risk eye.

References

• Chan CK, Abraham P, Meyer CH, et al. Optical coherence tomography-measured pigment epithelial detachment height as a predictor for retinal pigment epithelial tears associated with intravitreal bevacizumab injections. Retina.
• Clemens CR, Bastian N, Alten F, et al. Prediction of retinal pigment epithelial tear in serous pigment epithelial detachments. Acta Ophthalmologica.
• American Academy of Ophthalmology. Basic and Clinical Science Course, Section 12: Retina and Vitreous.